Subjects: Antibodies, Monoclonal, Humanized -- economics - Digital Collections - National Library of Medicine Search Results

Start Over Subjects Antibodies, Monoclonal, Humanized -- economics ✖ Publication Year 2000 to 2024 ✖

1. Anabolic therapies for osteoporosis in postmenopausal women: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, July 17, 2017
Subject(s):: Anabolic Agents -- therapeutic use
Antibodies, Monoclonal, Humanized -- therapeutic use
Osteoporosis, Postmenopausal -- drug therapy
Parathyroid Hormone-Related Protein -- therapeutic use
Anabolic Agents -- adverse effects
Anabolic Agents -- economics
Antibodies, Monoclonal, Humanized -- adverse effects
Antibodies, Monoclonal, Humanized -- economics
Bone Density Conservation Agents -- adverse effects
Bone Density Conservation Agents -- economics
Bone Density Conservation Agents -- therapeutic use
Comparative Effectiveness Research
Diphosphonates -- adverse effects
Diphosphonates -- economics
Diphosphonates -- therapeutic use
Osteoporotic Fractures -- prevention & control
Parathyroid Hormone-Related Protein -- adverse effects
Parathyroid Hormone-Related Protein -- economics
Randomized Controlled Trials as Topic
Teriparatide -- adverse effects
Teriparatide -- economics
Teriparatide -- therapeutic use
Humans
United States

2. Mepolizumab (Nucala??, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks : final report

Author(s):: Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Campbell, Jonathan D., author
Chapman, Rick, author
Shore, Karen K., author
Weissberg, Jed, author
Whittington, Melanie, author
Pearson, Steven D., author
Publication:: [Boston, MA] : Institute for Clinical and Economic Review, March 14, 2016
Subject(s):: Adrenergic beta-2 Receptor Agonists -- economics
Adrenergic beta-2 Receptor Agonists -- therapeutic use
Anti-Asthmatic Agents -- administration & dosage
Anti-Asthmatic Agents -- economics
Antibodies, Monoclonal, Humanized -- administration & dosage
Antibodies, Monoclonal, Humanized -- economics
Asthma -- drug therapy
Asthma -- immunology
Eosinophilia -- drug therapy
Interleukin-5 -- immunology
Cost-Benefit Analysis
Glucocorticoids -- administration & dosage
Humans
United States

3. Prophylaxis for hereditary angioedema with lanadelumab and C1 Inhibitors: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, November 25, 2018
Subject(s):: Angioedemas, Hereditary -- drug therapy
Angioedemas, Hereditary -- prevention & control
Antibodies, Monoclonal, Humanized -- therapeutic use
Complement C1 Inhibitor Protein -- therapeutic use
Kallikreins -- antagonists & inhibitors
Antibodies, Monoclonal, Humanized -- adverse effects
Antibodies, Monoclonal, Humanized -- economics
Complement C1 Inhibitor Protein -- adverse effects
Complement C1 Inhibitor Protein -- economics
Cost-Benefit Analysis
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States